- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
Trueblood Wealth Management Boosts Stake in AbbVie
The investment firm increased its holdings in the pharmaceutical company by over 40% in the fourth quarter.
Apr. 6, 2026 at 12:23pm
Got story updates? Submit your updates here. ›
Trueblood Wealth Management LLC, a financial advisory firm, boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 40.8% in the fourth quarter of 2025, according to the company's latest 13F filing with the Securities and Exchange Commission. The firm now owns 9,642 shares of the pharmaceutical company's stock, valued at approximately $2.2 million.
Why it matters
AbbVie is one of the largest pharmaceutical companies in the world, known for blockbuster drugs like Humira. Trueblood Wealth Management's increased investment in the company signals the firm's confidence in AbbVie's long-term growth prospects and ability to deliver returns for its clients.
The details
Trueblood Wealth Management added 2,793 shares of AbbVie to its portfolio during the fourth quarter, bringing its total holdings to 9,642 shares. The firm's investment in AbbVie now accounts for approximately 0.9% of its total assets under management. AbbVie's stock price has fluctuated in recent months, trading between a 52-week low of $164.39 and a high of $244.81.
- Trueblood Wealth Management reported its increased stake in AbbVie in its 13F filing for the fourth quarter of 2025.
- AbbVie's stock price reached a 52-week high of $244.81 during the reporting period.
The players
Trueblood Wealth Management LLC
A financial advisory firm that manages investments for its clients.
AbbVie Inc.
A global biopharmaceutical company that focuses on developing and commercializing therapies for complex and chronic medical conditions.
The takeaway
Trueblood Wealth Management's increased investment in AbbVie reflects the firm's confidence in the pharmaceutical company's long-term growth potential and ability to generate returns for its clients. As a major player in the healthcare industry, AbbVie's performance is closely watched by investors and analysts alike.
